Cellectar Biosciences, Inc. CLRB
We take great care to ensure that the data presented and summarized in this overview for Cellectar Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CLRB
Top Purchases
Top Sells
About CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Insider Transactions at CLRB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 08
2023
|
Andrei Shustov Senior Vice President, Medical |
BUY
Grant, award, or other acquisition
|
Direct |
47,856
+46.51%
|
-
|
|
Dec 08
2023
|
Chad J Kolean Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,554
+49.99%
|
-
|
|
Dec 08
2023
|
Darrell Shane Lea Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,599
+50.0%
|
-
|
|
Dec 08
2023
|
James V Caruso President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
40,596
+45.19%
|
-
|
|
Dec 08
2023
|
Jarrod Longcor Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,927
+44.68%
|
-
|
|
Sep 14
2021
|
Douglas J Swirsky Director |
BUY
Open market or private purchase
|
Direct |
25,000
+50.0%
|
$25,000
$1.04 P/Share
|
|
Sep 03
2021
|
Frederick W Driscoll Director |
BUY
Open market or private purchase
|
Direct |
19,417
+50.0%
|
$19,417
$1.04 P/Share
|
|
Mar 04
2021
|
James V Caruso President and CEO |
BUY
Open market or private purchase
|
Direct |
5,100
+5.57%
|
$5,100
$1.7 P/Share
|
|
Dec 28
2020
|
Dov Elefant Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
7,407
+38.65%
|
$7,407
$1.35 P/Share
|
|
Dec 28
2020
|
Jarrod Longcor Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
29,630
+22.48%
|
$29,630
$1.35 P/Share
|
|
Dec 28
2020
|
James V Caruso President and CEO |
BUY
Open market or private purchase
|
Direct |
37,037
+31.3%
|
$37,037
$1.35 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 214K shares |
|---|